Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Intranasal Morphine for Pain After Bunion Surgery

This study has been completed.
Information provided by:
Javelin Pharmaceuticals Identifier:
First received: October 12, 2006
Last updated: January 11, 2008
Last verified: January 2008

Study designed to evaluate the efficacy and safety of Intranasal (IN) Morphine Nasal Spray (MNS075) 3.75 mg, 7.5 mg, 15 mg, and 30 mg, intravenous (IV) morphine 7.5 mg, or IN placebo in patients with moderate to severe post-surgical pain following orthopedic surgery. After initial dosing, up to six (6) doses of IN MNS075 7.5 mg or 15 mg for up to twenty-four (24) hours will be evaluated. The rescue dose remained the same for each.

Condition Intervention Phase
Hallux Valgus
Drug: Intranasal Morphine (MNS075) 3.75 mg
Drug: Intravenous Morphine 7.5 mg
Drug: Intranasal morphine (MNS075) 7.5 mg
Drug: Intranasal morphine (MNS075) 15 mg
Drug: Intranasal morphine (MNS075) 30 mg
Drug: Intranasal placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo and Comparator-Controlled, Dose-Response Trial of the Efficacy and Safety of Intranasal Morphine, Intravenous Morphine and Placebo in Patients With Moderate to Severe Pain Following Orthopedic Surgery

Resource links provided by NLM:

Further study details as provided by Javelin Pharmaceuticals:

Primary Outcome Measures:
  • VAS Total Pain Relief 0-4 hours (TOTPAR4) [ Time Frame: 4 hours ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Other measures of pain relief [ Time Frame: Several time points ] [ Designated as safety issue: Yes ]

Enrollment: 187
Study Start Date: January 2005
Study Completion Date: August 2005
Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Intranasal morphine 3.75 mg
Drug: Intranasal Morphine (MNS075) 3.75 mg
Intranasal Morphine (MNS075) 3.75 mg
Experimental: 2
Intranasal morphine 7.5 mg
Drug: Intranasal morphine (MNS075) 7.5 mg
Intranasal morphine (MNS075) 7.5 mg
Experimental: 3
Intranasal morphine 15 mg
Drug: Intranasal morphine (MNS075) 15 mg
Intranasal morphine (MNS075) 15 mg
Experimental: 4
Intranasal morphine 30 mg
Drug: Intranasal morphine (MNS075) 30 mg
Intranasal morphine (MNS075) 30 mg
Active Comparator: 5
Intravenous morphine 7.5 mg
Drug: Intravenous Morphine 7.5 mg
Intravenous Morphine 7.5 mg
Placebo Comparator: 6
Intranasal placebo
Drug: Intranasal placebo
Intranasal placebo

Detailed Description:

Diagnosis and Main Criteria for Inclusion:

Healthy adult patients (18 to 76 years old), who scored PS-1 to PS-3 according to the American Society of Anesthesiologists Physical Status Classification System, requiring primary, unilateral, first metatarsal bunionectomy surgery alone or with ipsilateral hammertoe repair without additional collateral procedures.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Requires primary unilateral first metatarsal bunionectomy surgery alone or with ipsilateral hammertoe repair under regional anesthesia. The patient requires collateral orthopedic surgical procedures other than ipsilateral hammertoe repair may not be enrolled into the study.
  • 18 years of age or older
  • Moderate to severe pain within eight (8) hours following completion of the required bunionectomy surgery

Exclusion Criteria:

  • Allergy to shellfish
  • Signs of nasal congestion, nasal polyps, mucosal lesions of the nostrils, postnasal drip of any etiology or any clinically significant nasal pathology that may affect the absorption of study medication or the assessment of safety.
  • Chronic respiratory insufficiency such that treatment with an opioid analgesic is contraindicated

Additional Inclusion/Exclusion Criteria May Apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00388011

Sponsors and Collaborators
Javelin Pharmaceuticals
Principal Investigator: Douglas G Stoker, DPM Jean Brown Research
  More Information

No publications provided

Responsible Party: Amy Cohen/Director, Clinical Operations, Javelin Pharmaceuticals Identifier: NCT00388011     History of Changes
Other Study ID Numbers: MOR-002
Study First Received: October 12, 2006
Last Updated: January 11, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Javelin Pharmaceuticals:
Post surgical pain
Hammer Toe Syndrome

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on March 03, 2015